CoChat

Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices

Di Marco, Moreno, Schuster, Heiko, Backert, Linus, Ghosh, Michael, Rammensee, Hans-Georg, Stevanović, Stefan · 2017 · The Journal of Immunology
Cited by 111

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

The classical HLA-C and the nonclassical HLA-E and HLA-G molecules play important roles both in the innate and adaptive immune system. Starting already during embryogenesis and continuing throughout our lives, these three Ags exert major functions in immune tolerance, defense against infections, and anticancer immune responses. Despite these important roles, identification and characterization of the peptides presented by these molecules has been lacking behind the more abundant HLA-A and HLA-B gene products. In this study, we elucidated the peptide specificities of these HLA molecules using a comprehensive analysis of naturally presented peptides. To that end, the 15 most frequently expressed HLA-C alleles as well as HLA-E*01:01 and HLA-G*01:01 were transfected into lymphoblastoid C1R cells expressing low endogenous HLA. Identification of naturally presented peptides was performed by immunoprecipitation of HLA and subsequent analysis of HLA-bound peptides by liquid chromatographic tandem mass spectrometry. Peptide motifs of HLA-C unveil anchors in position 2 or 3 with high variances between allotypes, and a less variable anchor at the C-terminal end. The previously reported small ligand repertoire of HLA-E was confirmed within our analysis, and we could show that HLA-G combines a large ligand repertoire with distinct features anchoring peptides at positions 3 and 9, supported by an auxiliary anchor in position 1 and preferred residues in positions 2 and 7. The wealth of HLA ligands resulted in prediction matrices for octa-, nona-, and decamers. Matrices were validated in terms of their binding prediction and compared with the latest NetMHC prediction algorithm NetMHCpan-3.0, which demonstrated their predictive power.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1700938

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 85

  1. Zemmour, 1992, Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C, J. Exp. Med., 176, 937, 10.1084/jem.176.4.937 · DOI · Paper page
  2. Rech, 2017, T-cell transfer therapy targeting mutant KRAS, N. Engl. J. Med., 376, e11, 10.1056/NEJMc1616637 · DOI · Paper page
  3. Blais, 2011, HLA-C as a mediator of natural killer and T-cell activation: spectator or key player?, Immunology, 133, 1, 10.1111/j.1365-2567.2011.03422.x · DOI
  4. Trowsdale, 2008, NK receptor interactions with MHC class I molecules in pregnancy, Semin. Immunol., 20, 317, 10.1016/j.smim.2008.06.002 · DOI
  5. Falk, 1993, Allele-specific peptide ligand motifs of HLA-C molecules, Proc. Natl. Acad. Sci. USA, 90, 12005, 10.1073/pnas.90.24.12005 · doi:10.1073/pnas.90.24.12005
  6. Rasmussen, 2014, Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule, J. Immunol., 193, 4790, 10.4049/jimmunol.1401689 · doi:10.4049/jimmunol.1401689
  7. Braud, 1997, The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9, Eur. J. Immunol., 27, 1164, 10.1002/eji.1830270517 · DOI · Paper page
  8. Aldrich, 1994, Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen, Cell, 79, 649, 10.1016/0092-8674(94)90550-9 · doi:10.1016/0092-8674(94)90550-9
  9. Apps, 2015, Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells, J. Immunol., 194, 3594, 10.4049/jimmunol.1403234 · DOI
  10. Braud, 1998, HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C, Nature, 391, 795, 10.1038/35869 · DOI · Paper page
  11. Borrego, 2006, The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance, Immunol. Res., 35, 263, 10.1385/IR:35:3:263 · DOI · Paper page
  12. Malnati, 1995, Peptide specificity in the recognition of MHC class I by natural killer cell clones, Science, 267, 1016, 10.1126/science.7863326 · DOI · Paper page
  13. Fadda, 2010, Peptide antagonism as a mechanism for NK cell activation, Proc. Natl. Acad. Sci. USA, 107, 10160, 10.1073/pnas.0913745107 · DOI · Paper page
  14. Borhis, 2013, A peptide antagonist disrupts NK cell inhibitory synapse formation, J. Immunol., 190, 2924, 10.4049/jimmunol.1201032 · doi:10.4049/jimmunol.1201032
  15. King, 2000, HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells, Eur. J. Immunol., 30, 1623, 10.1002/1521-4141(200006)30:6<1623::AID-IMMU1623>3.0.CO;2-M · doi:10.1002/1521-4141(200006)30:6<1623::aid-immu1623>3.0.co;2-m
  16. Adams, 2013, The adaptable major histocompatibility complex (MHC) fold: structure and function of nonclassical and MHC class I-like molecules, Annu. Rev. Immunol., 31, 529, 10.1146/annurev-immunol-032712-095912 · DOI · Paper page
  17. Sullivan, 2006, A structural perspective on MHC class Ib molecules in adaptive immunity, Trends Immunol., 27, 413, 10.1016/j.it.2006.07.006 · DOI
  18. Curigliano, 2013, Molecular pathways: human leukocyte antigen G (HLA-G), Clin. Cancer Res., 19, 5564, 10.1158/1078-0432.CCR-12-3697 · DOI
  19. Lin, 2012, HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer, Int. J. Cancer, 131, 150, 10.1002/ijc.26375 · DOI
  20. Lila, 2000, Implication of HLA-G molecule in heart-graft acceptance, Lancet, 355, 2138, 10.1016/S0140-6736(00)02386-2 · DOI · Paper page
  21. Colonna, 1997, A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells, J. Exp. Med., 186, 1809, 10.1084/jem.186.11.1809 · DOI · Paper page
  22. Colonna, 1998, Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules, J. Immunol., 160, 3096, 10.4049/jimmunol.160.7.3096 · DOI · Paper page
  23. Rajagopalan, 1999, A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. [Published erratum appears in 2000 J. Exp. Med. 191: 1.], J. Exp. Med., 189, 1093, 10.1084/jem.189.7.1093 · DOI · Paper page
  24. Lee, 1995, The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association, Immunity, 3, 591, 10.1016/1074-7613(95)90130-2 · DOI · Paper page
  25. Diehl, 1996, Nonclassical HLA-G molecules are classical peptide presenters, Curr. Biol., 6, 305, 10.1016/S0960-9822(02)00481-5 · DOI · Paper page
  26. Zemmour, 1992, The HLA-A,B “negative” mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon, J. Immunol., 148, 1941, 10.4049/jimmunol.148.6.1941 · doi:10.4049/jimmunol.148.6.1941
  27. Storkus, 1987, NK susceptibility varies inversely with target cell class I HLA antigen expression, J. Immunol., 138, 1657, 10.4049/jimmunol.138.6.1657 · DOI · Paper page
  28. Yamada, 1999, Role of anchor residues in peptide binding to three HLA-A26 molecules, Tissue Antigens, 54, 325, 10.1034/j.1399-0039.1999.540401.x · DOI
  29. Dumrese, 1998, HLA-A26 subtype A pockets accommodate acidic N-termini of ligands, Immunogenetics, 48, 350, 10.1007/s002510050443 · DOI
  30. Shiga, 1996, Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules, AIDS, 10, 1075
  31. Kikuchi, 1996, Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket, Immunogenetics, 43, 268, 10.1007/BF02440994 · DOI
  32. Falk, 1995, Peptide motifs of HLA-B38 and B39 molecules, Immunogenetics, 41, 162, 10.1007/BF00182332 · DOI
  33. Falk, 1995, Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behćet’s disease, Int. Immunol., 7, 223, 10.1093/intimm/7.2.223 · DOI
  34. Falk, 1995, Peptide motifs of HLA-B58, B60, B61, and B62 molecules, Immunogenetics, 41, 165, 10.1007/BF00182333 · DOI
  35. Sidney, 1995, Several HLA alleles share overlapping peptide specificities, J. Immunol., 154, 247, 10.4049/jimmunol.154.1.247 · DOI · Paper page
  36. Falk, 1994, Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules, Immunogenetics, 40, 238, 10.1007/BF00167086 · DOI
  37. Abelin, 2017, Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction, Immunity, 46, 315, 10.1016/j.immuni.2017.02.007 · DOI · Paper page
  38. Andreatta, 2013, Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach, Bioinformatics, 29, 8, 10.1093/bioinformatics/bts621 · DOI
  39. Rammensee, 1999, SYFPEITHI: database for MHC ligands and peptide motifs, Immunogenetics, 50, 213, 10.1007/s002510050595 · DOI · Paper page
  40. Nielsen, 2016, NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets, Genome Med., 8, 33, 10.1186/s13073-016-0288-x · DOI · Paper page
  41. Robinson, 2015, The IPD and IMGT/HLA database: allele variant databases, Nucleic Acids Res., 43, D423, 10.1093/nar/gku1161 · DOI · Paper page
  42. Barnstable, 1978, Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis, Cell, 14, 9, 10.1016/0092-8674(78)90296-9 · DOI · Paper page
  43. Falk, 1991, Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules, Nature, 351, 290, 10.1038/351290a0 · DOI · Paper page
  44. Kowalewski, 2013, Biochemical large-scale identification of MHC class I ligands, Methods Mol. Biol., 960, 145, 10.1007/978-1-62703-218-6_12 · DOI · Paper page
  45. Eng, 1994, An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database, J. Am. Soc. Mass Spectrom., 5, 976, 10.1016/1044-0305(94)80016-2 · DOI · Paper page
  46. Steinle, 1996, Motif of HLA-B*3503 peptide ligands, Immunogenetics, 43, 105, 10.1007/BF00186615 · doi:10.1007/bf00186615
  47. Schittenhelm, 2014, A comprehensive analysis of constitutive naturally processed and presented HLA-C*04:01 (Cw4)-specific peptides, Tissue Antigens, 83, 174, 10.1111/tan.12282 · DOI · Paper page
  48. Thomsen, 2012, Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion, Nucleic Acids Res., 40, W281, 10.1093/nar/gks469 · DOI · Paper page
  49. Backert, 2015, Immunoinformatics and epitope prediction in the age of genomic medicine, Genome Med., 7, 119, 10.1186/s13073-015-0245-0 · DOI · Paper page
  50. Braud, 1998, TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide, Curr. Biol., 8, 1, 10.1016/S0960-9822(98)70014-4 · DOI · Paper page
  51. Strong, 2003, HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities, J. Biol. Chem., 278, 5082, 10.1074/jbc.M208268200 · DOI · Paper page
  52. Huyton, 2012, Pocketcheck: updating the HLA class I peptide specificity roadmap, Tissue Antigens, 80, 239, 10.1111/j.1399-0039.2012.01928.x · doi:10.1111/j.1399-0039.2012.01928.x
  53. del Guercio, 1995, Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype, J. Immunol., 154, 685, 10.4049/jimmunol.154.2.685 · DOI · Paper page
  54. Doytchinova, 2004, Identifying human MHC supertypes using bioinformatic methods, J. Immunol., 172, 4314, 10.4049/jimmunol.172.7.4314 · DOI · Paper page
  55. Barth, 2016, Characterization of the canine MHC class I DLA-88*50101 peptide binding motif as a prerequisite for canine T cell immunotherapy, PLoS One, 11, e0167017, 10.1371/journal.pone.0167017 · DOI
  56. Cheever, 2009, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research, Clin. Cancer Res., 15, 5323, 10.1158/1078-0432.CCR-09-0737 · DOI · Paper page
  57. Nielsen, 2003, Reliable prediction of T-cell epitopes using neural networks with novel sequence representations, Protein Sci., 12, 1007, 10.1110/ps.0239403 · DOI · Paper page
  58. Vita, 2015, The immune epitope database (IEDB) 3.0, Nucleic Acids Res., 43, D405, 10.1093/nar/gku938 · DOI · Paper page
  59. McCutcheon, 1995, Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA, J. Exp. Med., 181, 2085, 10.1084/jem.181.6.2085 · DOI · Paper page
  60. Neisig, 1998, Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction, J. Immunol., 160, 171, 10.4049/jimmunol.160.1.171 · DOI · Paper page
  61. Neefjes, 1988, Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association, Eur. J. Immunol., 18, 801, 10.1002/eji.1830180522 · DOI · Paper page
  62. Setini, 1996, Distinctive features of the alpha 1-domain alpha helix of HLA-C heavy chains free of beta 2-microglobulin, Hum. Immunol., 46, 69, 10.1016/0198-8859(96)00011-0 · DOI
  63. Mandelboim, 1997, The binding site of NK receptors on HLA-C molecules, Immunity, 6, 341, 10.1016/S1074-7613(00)80336-2 · DOI
  64. Boyington, 2001, Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules, Immunol. Rev., 181, 66, 10.1034/j.1600-065X.2001.1810105.x · DOI
  65. Colonna, 1993, HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells, Proc. Natl. Acad. Sci. USA, 90, 12000, 10.1073/pnas.90.24.12000 · DOI · Paper page
  66. Hilton, 2017, Missing or altered self: human NK cell receptors that recognize HLA-C, Immunogenetics, 69, 567, 10.1007/s00251-017-1001-y · DOI
  67. Chaux, 1999, Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1, J. Immunol., 163, 2928, 10.4049/jimmunol.163.5.2928 · DOI
  68. Breckpot, 2004, Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses, J. Immunol., 172, 2232, 10.4049/jimmunol.172.4.2232 · DOI
  69. Vantomme, 2003, A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16, Cancer Immun., 3, 17
  70. Heidecker, 2000, Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12, J. Immunol., 164, 6041, 10.4049/jimmunol.164.11.6041 · doi:10.4049/jimmunol.164.11.6041
  71. Boël, 1995, BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes, Immunity, 2, 167, 10.1016/S1074-7613(95)80053-0 · DOI · Paper page
  72. Van den Eynde, 1995, A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma, J. Exp. Med., 182, 689, 10.1084/jem.182.3.689 · DOI · Paper page
  73. Gnjatic, 2000, Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele, Proc. Natl. Acad. Sci. USA, 97, 10917, 10.1073/pnas.97.20.10917 · DOI
  74. Castelli, 1999, Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens, J. Immunol., 162, 1739, 10.4049/jimmunol.162.3.1739 · doi:10.4049/jimmunol.162.3.1739
  75. Friedman, 2004, Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate, Eur. J. Immunol., 34, 1091, 10.1002/eji.200324768 · DOI
  76. Redchenko, 2006, Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4, Immunology, 118, 50, 10.1111/j.1365-2567.2006.02338.x · DOI
  77. Nagata, 2005, Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient, Clin. Cancer Res., 11, 5265, 10.1158/1078-0432.CCR-04-2542 · DOI
  78. Tran, 2015, Immunogenicity of somatic mutations in human gastrointestinal cancers, Science, 350, 1387, 10.1126/science.aad1253 · DOI · Paper page
  79. Chiari, 1999, Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene, Cancer Res., 59, 5785
  80. Heinzel, 2002, HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells, J. Exp. Med., 196, 1473, 10.1084/jem.20020609 · DOI · Paper page
  81. Salerno-Gonçalves, 2004, Identification of a human HLA-E-restricted CD8+ T cell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine, J. Immunol., 173, 5852, 10.4049/jimmunol.173.9.5852 · DOI · Paper page
  82. Romagnani, 2004, HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes, Hum. Immunol., 65, 437, 10.1016/j.humimm.2004.02.001 · DOI
  83. García, 2002, Human T cell receptor-mediated recognition of HLA-E, Eur. J. Immunol., 32, 936, 10.1002/1521-4141(200204)32:4<936::AID-IMMU936>3.0.CO;2-M · doi:10.1002/1521-4141(200204)32:4<936::aid-immu936>3.0.co;2-m
  84. Housseau, 1999, Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells, J. Immunol., 163, 6330, 10.4049/jimmunol.163.11.6330 · DOI
  85. Lampen, 2013, Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2, Mol. Immunol., 53, 126, 10.1016/j.molimm.2012.07.009 · DOI

Cited by

See all 111

Metadata

Authors
Di Marco, M., Schuster, H., Backert, L., Ghosh, M., Rammensee, H.-G., & Stevanović, S.
Affiliations
Department of Immunology, Institute for Cell Biology, University of Tübingen , 72076 Tübingen,
Venue
The Journal of Immunology
Published
2017-10
Volume
199
Issue
8
Pages
2639-2651
ISSN
  • 0022-1767
  • 1550-6606
Cited by
111
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.